Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | AEON Biopharma, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
11.06. | AEON Biopharma, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
23.05. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 161 | GlobeNewswire (Europe) | IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
20.05. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | AEON Biopharma GAAP EPS of $2.28 | 1 | Seeking Alpha | ||
14.05. | AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | 128 | GlobeNewswire (Europe) | - Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
25.04. | NYSE American accepts AEON Biopharma's plan to regain listing | 1 | Seeking Alpha | ||
25.04. | AEON Biopharma erhält Zustimmung der NYSE American für Compliance-Plan | 1 | Investing.com Deutsch | ||
25.04. | AEON Biopharma gets NYSE American nod for compliance plan | 1 | Investing.com | ||
25.04. | AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance | 688 | GlobeNewswire (Europe) | IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma ernennt Rob Bancroft zum neuen CEO | 2 | Investing.com Deutsch | ||
21.04. | AEON Biopharma names Rob Bancroft as new CEO | 1 | Investing.com | ||
21.04. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
21.04. | AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer | 651 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 118 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
08.04. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.03. | AEON Biopharma announces leadership change amid growth strategy | 1 | Investing.com | ||
27.03. | AEON Biopharma kündigt Führungswechsel | 1 | Investing.com Deutsch | ||
24.03. | AEON Biopharma GAAP EPS of $3.75 | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ALTERITY THERAPEUTICS | 0,006 | 0,00 % | ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
BIOCURE TECHNOLOGY | 0,032 | +23,08 % | Biocure Technology Inc (2): Biocure shareholders approve all matters at AGM | ||
QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
BEAM THERAPEUTICS | 17,620 | -1,34 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
JANUX THERAPEUTICS | 22,830 | +1,11 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
EVOTEC | 6,778 | +1,35 % | Aktien KW 31 Schwache Zahlen, BAFin, Zollhammer 2.0, Arbeitsmarktzahlen - jetzt Sommerloch? News. Cancom. Mutares. Evotec. SFC Energy. GEA Group. Knorr Bremse. Fuchs. Nemetschek. Villeroy & Boch. Befesa. KION. SAF Holland. Nordex. STEYR Motors. mVise. The | Aktien: Diese Woche ging es eigentlich noch ganz entspannt los, die 24.000er Mauer umkämpft, aber der Markt schien relativ sicher gegen tiefe Abstürze, Donnerstag schloss der Juli noch mit einem kleinen... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 46,240 | -2,69 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 32,150 | -2,90 % | Gold Fields, Kiniksa Join Best Stock Lists As They Defy Slump And Shares Pop: See New Names On IBD 50, IPO Leaders And More | ||
COGENT BIOSCIENCES | 10,960 | +0,83 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
ARS PHARMACEUTICALS | 17,500 | -0,85 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
ADMA BIOLOGICS | 16,525 | -1,34 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 6,100 | +1,16 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
ARCELLX | 70,53 | -0,87 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
AMYLYX PHARMACEUTICALS | 7,640 | -2,55 % | Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline |